🇺🇸 FDA
Patent

US 11261444

Organic compositions to treat EPAS1-related diseases

granted A61KA61K31/7105A61K31/7115

Quick answer

US patent 11261444 (Organic compositions to treat EPAS1-related diseases) held by Arrowhead Pharmaceuticals, Inc. expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/7105, A61K31/7115, A61K31/712, A61K31/7125